Journal of Clinical Endocrinology & Metabolism, Vol 71, 1632-1636, Copyright © 1990 by Endocrine Society

ARTICLES

Insulin-dependent regulation of insulin-like growth factor-binding protein-1

DK Snyder and DR Clemmons
Department of Medicine, East Carolina University, Greenville, NC 27834.

In previous studies it has been determined that food ingestion or glucose infusion suppresses serum insulin-like growth factor-binding protein-1 (IGFBP-1) concentrations in normal subjects. It has not been determined, however, whether glucose-dependent suppression is due to enhancement of insulin-stimulated glucose transport, to some other insulin-mediated effect, or to a direct effect of glucose. These studies were undertaken to determine if infusion of other nutrients or energy sources that activate glycolysis, but not insulin secretion, could lead to suppression of the plasma concentrations of this protein. After infusion of 50 g glucose over 4 h, the mean plasma IGFBP-1 concentration fell from 44.3 +/- 13.8 to 17.4 +/- 8.1 micrograms/L (P less than 0.001). In contrast, when 50 g fructose were infused over 4 h, IGFBP-1 decreased from 44.6 +/- 7.4 to only 32.7 +/- 6.7 micrograms/L (P less than 0.01). Comparison of these changes showed that the mean decrease after glucose infusion was significantly greater than that after fructose (P less than 0.01). In contrast to these decreases, infusion of an isocaloric amount of triglycerides resulted in no significant change in IGFBP-1 concentrations (from 49.8 +/- 14.1 to 40.2 + 10.4 micrograms/L; P = NS). Concomitant measurements of immunoreactive C-peptide during the glucose and fructose infusions showed that plasma C-peptide levels rose from 1.6 +/- 0.2 to 3.9 +/- 0.7 nM (P less than 0.001) during the glucose infusion, whereas the maximum increase was from 1.7 +/- 0.4 to only 2.3 +/- 0.4 nM (P less than 0.05) during the fructose infusion. The difference between these mean changes was also significant. The change in C-peptide correlated inversely with the changes in IGFBP-1 during the glucose infusion (r = - 0.68); P less than 0.001), but not during fructose infusion (r = - 0.31). The results of this study suggest that insulin stimulation of cellular metabolic pathways is an important variable regulating the suppression of plasma IGFBP-1 concentrations. Activation of noninsulin- dependent glycolytic pathways appears to result in an equivalent degree of suppression, whereas provision of other energy substrates has no effect. We conclude that both insulin and glucose are important regulators of plasma concentrations of IGFBP-1 in vivo, and in this way they may significantly influence IGF action.

This article has been cited by other articles:

				B. M. Wolpin, D. S. Michaud, E. L. Giovannucci, E. S. Schernhammer, M. J. Stampfer, J. E. Manson, B. B. Cochrane, T. E. Rohan, J. Ma, M. N. Pollak, et al. Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer Cancer Res., August 15, 2007; 67(16): 7923 - 7928. [Abstract] [Full Text] [PDF]

				T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013. [Abstract] [Full Text] [PDF]

				M. Shimizu, B. R Beckman, A. Hara, and W. W Dickhoff Measurement of circulating salmon IGF binding protein-1: assay development, response to feeding ration and temperature, and relation to growth parameters J. Endocrinol., January 1, 2006; 188(1): 101 - 110. [Abstract] [Full Text] [PDF]

				J. Svensson, H. Herlitz, P.-A. Lundberg, and G. Johannsson Adiponectin, Leptin, and Erythrocyte Sodium/Lithium Countertransport Activity, But Not Resistin, Are Related to Glucose Metabolism in Growth Hormone-Deficient Adults J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2290 - 2296. [Abstract] [Full Text] [PDF]

				C. F. Liew, S. D. Wise, K. P. Yeo, and K. O. Lee Insulin-Like Growth Factor Binding Protein-1 Is Independently Affected by Ethnicity, Insulin Sensitivity, and Leptin in Healthy, Glucose-Tolerant Young Men J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1483 - 1488. [Abstract] [Full Text] [PDF]

				D. Mesotten, P. J. D. Delhanty, F. Vanderhoydonc, K. V. Hardman, F. Weekers, R. C. Baxter, and G. van den Berghe Regulation of Insulin-Like Growth Factor Binding Protein-1 during Protracted Critical Illness J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5516 - 5523. [Abstract] [Full Text] [PDF]

				L. E. L. Katz, D. D. DeLeon, H. Zhao, and A. F. Jawad Free and Total Insulin-Like Growth Factor (IGF)-I Levels Decline during Fasting: Relationships with Insulin and IGF-Binding Protein-1 J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2978 - 2983. [Abstract] [Full Text] [PDF]

				L. E. Levitt Katz, M. S. Satin-Smith, P. Collett-Solberg, L. Baker, C. A. Stanley, and P. Cohen Dual Regulation of Insulin-Like Growth Factor Binding Protein-1 Levels by Insulin and Cortisol during Fasting J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4426 - 4430. [Abstract] [Full Text]

				J. Nakae, M. Kato, M. Murashita, N. Shinohara, T. Tajima, and K. Fujieda Long-Term Effect of Recombinant Human Insulin-Like Growth Factor I on Metabolic and Growth Control in a Patient with Leprechaunism J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 542 - 549. [Abstract] [Full Text]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				C. A. Benbassat, K. C. Maki, and T. G. Unterman Circulating Levels of Insulin-Like Growth Factor (IGF) Binding Protein-1 and -3 in Aging Men: Relationships to Insulin, Glucose, IGF, and Dehydroepiandrosterone Sulfate Levels and Anthropometric Measures J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1484 - 1491. [Abstract] [Full Text] [PDF]

				R. V. Bhat, T. M. Engber, Y. Zhu, M. S. Miller, and P. C. Contreras Identification of Insulin-Like Growth Factor Binding Protein-2 as a Biochemical Surrogate Marker for the in Vivo Effects of Recombinant Human Insulin-Like Growth Factor-1 in Mice J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 522 - 530. [Abstract] [Full Text]